Our History

2022

2023

Agenus completes enrollment in randomized Phase 2 clinical trial of botensilimab/balstilimab in advanced MSS colorectal cancer

Agenus presents survival data for botensilimab/balstilimab in advanced MSS colorectal cancer during late-breaking oral presentation at ESMO-GI

Agenus receives Fast Track Designation for botensilimab and balstilimab in MSS colorectal cancer

MiNK Therapeutics presents clinical activity and long-term persistence of allogeneic iNKT cells in solid tumors at SITC 2023

SaponiQx advances vaccine development with the availability of cGMP QS-21 from its proprietary cultured plant cell source

2022

Agenus presents clinical data on botensilimab (next-gen CTLA-4)/balstilimab (PD-1) combination in heavily pretreated, treatment-resistant solid tumors

AGEN1571 (anti-ILT2) enters clinical development

2021

Agenus and BMS enter licensing agreement for AGEN1777 (TIGIT bispecific)

AGEN1777 enters clinical development

Agenus presents data on botensilimab (next-gen CTLA-4) in solid tumors

Agenus publishes data on balstilimab (PD-1)/zalifrelimab (CTLA-4) combination in 2L cervical cancer

Agenus subsidiary MiNK Therapeutics announces IPO and becomes publicly traded on Nasdaq under the symbol INKT

Agenus subsidiary SaponiQx launches to drive innovation in adjuvant manufacturing, novel adjuvant discovery, and vaccine design

2020

Agenus and Betta enter licensing agreement for balstilimab (PD-1) and zalifrelimab (CTLA-4) in greater China

2019

Botensilimab (next-gen CTLA-4), AGEN2373 (CD137), and AGEN1423 (CD73-TGFβ) enter clinical development

Agenus and UroGen enter zalifrelimab collaboration for intravesical treatment of urinary tract cancers

2018

MK-4830 (ILT4), INCAGN2385 (LAG-3) and INCAGN02390 (TIM-3) enter clinical development

Agenus and Gilead enter collaboration to develop next-generation immuno-oncology therapies

2017

Balstilimab (PD-1) enters clinical development

FDA approves GSK’s Shingrix® containing QS-21 Stimulon™

2016

Zalifrelimab (CTLA-4); INCAGN1949 (GITR) and INCAGN2385 (OX40) enter clinical development

2015

Agenus and Incyte enter global I-O discovery alliance

Agenus acquires XOMA manufacturing plant and talent

2014

Agenus acquires 4-AB with multiple checkpoint antibody programs

Agenus and Merck enter antibody discovery collaboration

2006

Prophage evaluated in largest neoantigen vaccine Ph3 trial in adjuvant renal cell carcinoma

2000

Agenus completes IPO and becomes publicly traded on Nasdaq under the symbol AGEN

Agenus acquires Aquila Biopharmaceuticals and QS-21 Stimulon™

1999+

Prophage reveals robust clinical responses in melanoma, renal cell carcinoma, colorectal cancer, and other indications

1994

Agenus (previously Antigenics) founded to develop first individualized neoantigen vaccine, Prophage